p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 1943-1948

  Ferronika, Paranita ^a   Triningsih, F X Ediati ^a   Ghozali, Ahmad ^a   Moeljono, Abraham ^a   Rahmayanti, Siti ^a   Shadrina, Arifah Nur ^a   Naim, Awang Emir ^a   Wudexi, Ivan ^a   Arnurisa, Alfa Monica ^a   Nanwani, Sandeep Tarman ^a   Harijadi, Ahmad ^a  

^a GADJAH MADA UNIVERSITY   (Indonesia)

Author keywords

ALDH1A1; Cancer stem cell; p63; Prostate cancer

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDH1A1 PROTEIN, HUMAN; KI 67 ANTIGEN; TP63 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER STEM CELL; CELL PROLIFERATION; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; CYTOPLASM; ENZYME IMMUNOASSAY; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

AGED; AGED, 80 AND OVER; ALDEHYDE DEHYDROGENASE; APOPTOSIS; CELL PROLIFERATION; CROSS-SECTIONAL STUDIES; CYTOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASTIC STEM CELLS; PROGNOSIS; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84872677597     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.1943     Document Type: Article

References (34)

1. Aihara M, Truong LD, Dunn JK, et al (1994). Frequency of apoptotic bodies positively correlates with Gleason score in prostate cancer. Hum Pathol, 25, 797-801.
2. Boldrup L, Coates PJ, Gu X, Nylander (2007). δNp63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol, 213, 384-91.
3. Carroll DK, Carroll JS, Leong CO, et al (2006). p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol, 8, 551-61
4. Chute JP, Muramoto GG, Whitesides J, et al (2006) Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA, 31, 11707-12.
5. Cookson MS, Aus G, Burnett AL, et al (2007). Variation in the definition of biochemical recurrence in patients treated for localized prostatecancer: the American urological association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol, 177, 540-5.
6. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 65, 10946-51.
7. Dachille G, Cai T, Ludovicoi GM, et al (2008). Prognostic role of cell apoptotic rate in prostate cancer: Outcome of a long-time follow-up study. Oncology reports, 19, 541-5.
8. Dhillon PK, Barry M, Stampfer MJ, et al (2009). Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev, 18, 595-600.
9. Di Como CJ, Urist MJ, Babayan I, et al (2002). p63 expression profiles in human normal and tumor tissues. Clin Cancer Res, 8, 494-501.
10. Dohn M, zhang S, Chen X (2001). p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene, 20, 3193-205.
11. Du Z, Li J, Wang L, et al (2010). Overexpression of δNp63α induces a stem cell phenotype in MCF7 breast carcinoma cell line through the Notch pathway. Cancer Sci, 101, 2417-24.
12. Duester G (2000). Families of retinoid dehydrogenases regulating vitamin A function: production of visual pigment and retinoic acid. Eur J Biochem, 267, 4315-24.
13. Eble JN, sauter G, Epstein JI, Sesterhenn IA (2004). Pathology and genetics of tumours of the urinary sytem and male genital organs. IARC Press. Lyon.
14. Ferlay J, Shin HR, Bray F, et al (2001). GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from: http://globocan.iarc.fr.
15. Ginestier C, Hur MH, Charafe-Jauffret E, et al (2007). ALDH1 is a marker of normal and malignant human mammry stem cells and predictor of poor clinical outcome. Cell Stem Cell, 1, 555-67.
16. Humphrey PA (2004). Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology, 17, 292-306
17. Landen CN, Goodman B, Katre1 AA, et al (2010) Targeting Aldehyde Dehydrogenase Cancer Stem Cells in Ovarian Cancer. Mol Cancer Ther, 9, 3186-99.
18. Li T, Su Y, Mei Y, et al (2010). ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab Invest, 90, 234-44.
19. Magni M, Shammah S, Schiro R, et al (1996). Induction of cyclophosphamide-resistance by aldehyde-dehydrogenase gene transfer. Blood, 87, 1097-103.
20. Mills AA, Zheng B, Wang XJ, et al (1999). p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature, 398, 708-13.
21. Narahashi T, Niki T, Wang T, et al (2006). Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology, 49, 349-57.
22. Nylander K, Vojtesek B, Nenutil R, et al (2002). Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol, 198, 417-27.
23. Pardal R, Clarke MF, Morrison SJ (2003). Applying the principles of stem-cell biology to cancer. Nat Rev Cancer, 3, 895-902.
24. Patrawala L, Calhoun T, Schneider-Broussard R, et al (2006). Highly purified CD44(+) prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 25, 1696-708.
25. Reiner T, De las Pozas A, Parrondo R, Perez-Stable C (2007). Progression of prostate cancer from a subset of p63-positive basal epithelial cells in FG/Tag transgenic mice. Mol Cancer Res, 5, 1171-9.
26. Senoo M, Pinto F, Crum CP, McKeon F (2007). p63 Is Essential for the Proliferative Potential of Stem Cells in Stratified Epithelia. Cell, 129, 523-36.
27. Signoretti S, Waltregny D, Dilks J, et al (2000). p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol, 157, 1769-75.
28. Sophos NA, Vasiliou V (2003). Aldehyde dehydrogenase gene superfamily: the 2002 update. Chem Biol Interact, 143, 5-22.
29. Van Den Hoogen C, Van Der Horst G, Cheung H, et al (2010). High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res, 70, 5163-73.
30. Vigneswaran N, Baucum D, Wu J, et al (2007). Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression. BMC Cancer, 7, 108.
31. Yang A, Kaghad M, Wang Y, et al (1998). p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell, 2, 305-16.
32. Yang A, Schweitzer R, Sun D, et al (1999). p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature, 398, 714-8.
33. Yoshida A, Rzhetsky A, Hsu LC, Chang C (1998). Human aldehyde dehydrogenase gene family. Eur J Biochem, 251, 549-57.
34. Zucchi I, Astigiano S, Bertalot G, et al (2008). Distinct populations of tumor-initiating cells derived from a tumor generated by rat mammary cancer stem cells. Proc Natl Acad Sci U S A, 105, 16940-5.